Research
Hormonal
Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.
If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.
StrongSupportsHIGH confidence
Bezüglich harter Endpunkte konnte die SELECT-Studie für schwere unerwünschte kardiovaskuläre Ereignisse (MACE) eine Risikoreduktion von 20 % unter Semaglutid zeigen.
Why this rating
Based on the SELECT study, a large, randomized, double-blind, placebo-controlled trial.
Source
Peptidhormonanaloga basierte medikamentöse Adipositastherapie ist effektiv
M. Azhar Hussain et al. · Die Chirurgie · 2025
DOI 10.1007/s00104-025-02402-z
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →